Ang II-Induced Cardiac Hypertrophy Mouse Model
Objective: Test pharmacological inhibition of miR-21* in a mouse model of Ang II-induced cardiac hypertrophy to determine if miR-21* inhibition attenuates pathological cardiac remodeling
This is a Ang II-Induced Cardiac Hypertrophy Mouse Model protocol using mouse as the model organism. The procedure involves 3 procedural steps, 2 materials. Extracted from a 2014 paper published in Journal of Clinical Investigation.
Model and subjects
mouse • Not specified in provided text • unknown • Not specified in provided text • Not specified in provided text
Study window
Estimated timing pending
Core workflow
Establish Ang II-induced cardiac hypertrophy mouse model • Administer pharmacological miR-21* inhibitor • Assess cardiac pathology
Primary readouts
- Cardiac hypertrophy severity
- Cardiac fibrosis extent
- Pathological cardiac remodeling markers
Key equipment and reagents
Use this page as an execution guide, then fall back to the source paper whenever you need exact exclusions, dosing details, or assay-specific caveats.
Confirm first
- Verify the animal model, intervention setup, and collection timepoints against the source paper.
- Check that every direct vendor link matches the exact specification your lab plans to run.
Use the page like this
- Work through the protocol steps in order and use the inline vendor chips only when you need to source or verify an item.
- Jump to Experimental Context for readouts, data shape, and analysis flow before planning downstream analysis.
Protocol Steps
Start here. The step list is optimized for running the experiment, with direct vendor links available inline when you need to source a cited item.
Establish Ang II-induced cardiac hypertrophy mouse model
Induce cardiac hypertrophy in mice using Angiotensin II treatment
Note: This is the disease model used to test miR-21* inhibition
View evidence from paper
“Pharmacological inhibition of miR-21* in a mouse model of Ang II–induced cardiac hypertrophy attenuated pathology”
Administer pharmacological miR-21* inhibitor
Treat mice with pharmacological inhibitor of miR-21* in the context of Ang II-induced cardiac hypertrophy
Note: Treatment designed to test whether miR-21* inhibition can attenuate pathological cardiac remodeling
View evidence from paper
“Pharmacological inhibition of miR-21* in a mouse model of Ang II–induced cardiac hypertrophy attenuated pathology”
Assess cardiac pathology
Evaluate cardiac hypertrophy and fibrosis outcomes following miR-21* inhibition treatment
Note: Pathology assessment to determine if miR-21* inhibition attenuates disease phenotype
View evidence from paper
“Pharmacological inhibition of miR-21* in a mouse model of Ang II–induced cardiac hypertrophy attenuated pathology”